Marrow and lymph-node pathological diagnosis
Architecture and phenotype complement one another
A lymph-node aspirate, cell block, core and excision provide different amounts of architectural information. A clonal B-cell population supports a lymphoproliferative assessment but is not enough to assign every subtype. Cell size, distribution, background, phenotype, genetics and clinical context are integrated. CD5, CD23, cyclin D1 and other markers help distinguish patterns without making every case conform to a perfect textbook panel. A negative expected marker can require further assessment rather than automatic exclusion of a known variant.
Avoid single-marker definitions
Reed-Sternberg-like cells occur outside classical Hodgkin lymphoma, and CD30 is not exclusive to that diagnosis. A compatible background and an appropriate panel are important. MYC rearrangement can occur in more than one aggressive B-cell tumor and does not independently prove Burkitt lymphoma. Similarly, an associated BCL2 rearrangement supports a follicular differential in the right context but is not a uniquely diagnostic finding in every specimen. Flow cytometry and immunohistochemistry have specimen and technical limitations, including viability, sampling and incomplete representation of the lesion.
Marrow categories need actual criteria
Count changes, smear findings, cellularity, maturation, dysplasia, fibrosis and blast assessment contribute to a marrow diagnosis. A low count is not proof that production is the only failing process. Myeloid classification depends on the specified edition and defining genetics, with relevant thresholds and exclusions. An isolated del(5q) label cannot be assigned indiscriminately when blast findings cross the threshold for that entity. Molecular clonality and a clinical neoplasm are not identical concepts. A defining rearrangement must be interpreted with lineage and disease context rather than simply named from a positive assay.
Clinical pathological integration
Schistocytes, iron studies, antiglobulin testing and protein assessments link morphology with functional disease mechanisms. A severe ADAMTS13 deficiency in an appropriate thrombotic-microangiopathy presentation has a different implication from nonspecific anemia and thrombocytopenia alone. Plasma-cell disease requires interpretation of clonality, burden and appropriately attributed defining events. Transfusion-related findings can require urgent recognition even when the final mechanism remains under investigation. The pathology report should communicate important findings promptly, distinguish certainty levels and state whether a limited sample prevents a definitive subtype. Diagnostic cooperation supports appropriate care without claiming that a written bank establishes independent treatment or procedural competence.